Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 21 July, 2024
Author: Getaka|Social: Getaka Financial Services X (Earlier Twitter) Profile Getaka Financial Services LinkedIn Logo

Fundamental Analysis of Neuland Laboratories Ltd

About the Company - Neuland Laboratories Ltd

Neuland Laboratories Ltd. is a Public Limited Listed company incorporated on 07/01/1984 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L85195TG1984PLC004393 and registration number is 004393. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 951.08 Cr. and Equity Capital is Rs. 12.90 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals11th Floor (5th Office Level), Phoenix IVY Building, Hyderabad Telangana 500033ir@neulandlabs.com
http://www.neulandlabs.com
Management
NamePosition Held
Dr. Davuluri Rama Mohan RaoExecutive Chairman
Mr. Davuluri Sucheth RaoVice Chairman & CEO
Mr. Davuluri Saharsh RaoVice Chairman & Mng.Director
Dr. Christopher M CimarustiNon Executive Director
Dr. Nirmala MurthyIndependent Director
Mr. Homi Rustum KhusrokhanIndependent Director
Mr. Prasad Raghava MenonIndependent Director
Mr. Sugata SircarIndependent Director
Ms. Pallavi Joshi BakhruIndependent Director

Basic Stock Data of Neuland Laboratories Ltd

Last Updated: July 20, 2024, 10:48 pm

Market Cap 10,431 Cr.
Current Price 8,130
High / Low8,650/3,100
Stock P/E34.7
Book Value 1,000
Dividend Yield0.17 %
ROCE33.3 %
ROE26.4 %
Face Value 10.0
PEG Ratio0.43

Data Source: screener.in

Competitors of Neuland Laboratories Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Kwality Pharmaceuticals Ltd 518 Cr. 499590/30917.7 2180.00 %15.9 %13.7 % 10.0
Jubilant Pharmova Ltd 11,940 Cr. 750800/31951.0 3410.67 %6.74 %0.76 % 1.00
Bafna Pharmaceuticals Ltd 201 Cr. 85.0119/73.227.4 34.20.00 %9.55 %9.53 % 10.0
BDH Industries Ltd 194 Cr. 336404/16219.6 1081.34 %20.6 %16.9 % 10.0
Syncom Formulations (India) Ltd 1,438 Cr. 15.318.6/7.1560.8 3.050.00 %10.4 %8.72 % 1.00
Industry Average16,783.88 Cr1,212.7944.07199.680.36%17.04%16.30%6.44

Neuland Laboratories Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales245245201258236256221294269407363418393
Expenses199219175215204217193224215287266280272
Operating Profit47262643323929695412097137121
OPM %19%10%13%17%14%15%13%24%20%29%27%33%31%
Other Income01520211018232
Interest4544333334244
Depreciation10111212131213131313141515
Profit before tax32241228182413533911083122104
Tax %16%29%28%26%29%10%26%28%22%23%26%27%22%
Net Profit2717920132210383185628981
EPS in Rs20.8413.486.8015.8810.0916.987.7729.9823.8165.8948.2369.5663.44

Last Updated: July 11, 2024, 11:35 am

Neuland Laboratories Ltd Quarterly Chart

Neuland Laboratories Ltd Profit & Loss

Last Updated: July 10, 2024, 8:09 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales4484614664695105795276677639379511,1911,581
Expenses4014023954024304724776086617908079181,105
Operating Profit47587167801065158102147144273476
OPM %11%13%15%14%16%18%10%9%13%16%15%23%30%
Other Income233021434160915
Interest33312527242119162218141315
Depreciation15151515161922263140495357
Profit before tax1163525426714205310582216419
Tax %-210%12%23%36%36%30%13%19%69%23%22%24%
Net Profit314271627471216168164164317
EPS in Rs2.8815.5730.1217.9630.7552.7413.5712.8112.6362.8549.74127.45247.12
Dividend Payout %0%7%9%8%7%0%0%0%16%8%10%8%

Neuland Laboratories Ltd Profit & Loss Yearly Chart

Neuland Laboratories Ltd Growth

Compounded Sales Growth
10 Years:13%
5 Years:19%
3 Years:18%
TTM:31%
Compounded Profit Growth
10 Years:27%
5 Years:79%
3 Years:62%
TTM:83%
Stock Price CAGR
10 Years:38%
5 Years:76%
3 Years:57%
1 Year:171%
Return on Equity
10 Years:12%
5 Years:14%
3 Years:18%
Last Year:26%

Last Updated: July 17, 2024, 5:22 pm

Neuland Laboratories Ltd Balance Sheet

Last Updated: July 10, 2024, 8:09 pm

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital5889999131313131313
Reserves71921161521785375496866977748289811,120
Borrowings220211190188182192319231264182241128101
Other Liabilities130114169162155148194200257356302457431
Total Liabilities4264254835125248861,0711,1301,2311,3251,3831,5801,665
Fixed Assets151136131123139466475542653716767758800
CWIP2736354140201261042417204112
Investments7777788887410
Other Assets240246311340337393463476547585592781853
Total Assets4264254835125248861,0711,1301,2311,3251,3831,5801,665

Neuland Laboratories Ltd Reserves and Borrowings Chart

Neuland Laboratories Ltd Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity 264913453911705718960237261
Cash from Investing Activity -7-10-14-20-42-116-77-49-84-95-61-150
Cash from Financing Activity -20-391-24-010512-5-11438-136-69
Net Cash Flow-1-001-4-053-934042

Neuland Laboratories Ltd Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days7893100851141349091859011187
Inventory Days124138170182186266191209205227211222
Days Payable110139167121118189118110126100129121
Cash Conversion Cycle9292103147182211162190164216193188
Working Capital Days7689124115139176126131931249698
ROCE %15%19%16%18%16%4%4%8%11%10%21%

Neuland Laboratories Ltd Financial Efficiency Indicators Chart

Neuland Laboratories Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters36.22%36.22%36.22%36.22%36.22%36.22%36.22%36.14%36.14%36.03%35.97%32.80%
FIIs17.21%15.51%16.03%17.21%17.21%17.39%17.68%17.70%18.14%20.19%21.57%22.69%
DIIs5.30%4.42%5.65%6.17%6.38%6.45%6.57%6.54%7.10%6.76%6.99%6.02%
Government0.00%0.00%0.00%0.00%0.00%0.00%0.44%0.46%0.40%0.40%0.40%0.40%
Public41.27%43.85%42.10%40.40%40.19%39.94%39.07%39.15%38.22%36.62%35.08%38.10%
No. of Shareholders22,41234,97834,33232,42632,25731,97630,60029,66926,94825,22326,82427,723

Neuland Laboratories Ltd Shareholding Pattern Chart

No. of Neuland Laboratories Ltd Shareholders

Neuland Laboratories Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Quant Small Cap Fund116,4490.5763.66116,4492024-07-200%
WhiteOak Capital Flexi Cap Fund57,7561.1931.57116,4492024-07-20-50.4%
WhiteOak Capital Mid Cap Fund27,5051.1515.04116,4492024-07-20-76.38%
WhiteOak Capital Multi Cap Fund11,0911.176.06116,4492024-07-20-90.48%
Motilal Oswal Nifty Microcap 250 Index Fund9,0880.874.97116,4492024-07-20-92.2%
WhiteOak Capital Balanced Advantage Fund7,5320.564.12116,4492024-07-20-93.53%
WhiteOak Capital ELSS Tax Saver Fund2,4831.231.36116,4492024-07-20-97.87%
WhiteOak Capital Large Cap Fund2,1110.311.15116,4492024-07-20-98.19%
WhiteOak Capital Multi Asset Allocation Fund1,8820.421.03116,4492024-07-20-98.38%
WhiteOak Capital Balanced Hybrid Fund7620.550.42116,4492024-07-20-99.35%

Neuland Laboratories Ltd ROCE Trend

Neuland Laboratories Ltd EPS Trend

Neuland Laboratories Ltd Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)233.89127.4549.7462.8512.63
Diluted EPS (Rs.)233.89127.4549.7462.8512.63
Cash EPS (Rs.)278.89167.6687.4993.2636.81
Book Value[Excl.RevalReserv]/Share (Rs.)994.31769.94650.88608.98549.68
Book Value[Incl.RevalReserv]/Share (Rs.)994.31770.59651.52609.63550.33
Revenue From Operations / Share (Rs.)1208.16923.37737.24726.26591.23
PBDIT / Share (Rs.)368.31218.28112.16126.2981.99
PBIT / Share (Rs.)322.03177.3774.1595.5257.75
PBT / Share (Rs.)311.18167.2463.6981.6541.02
Net Profit / Share (Rs.)232.61126.7549.4762.5012.57
NP After MI And SOA / Share (Rs.)232.61126.7549.4762.5012.57
PBDIT Margin (%)30.4823.6315.2117.3813.86
PBIT Margin (%)26.6519.2010.0513.159.76
PBT Margin (%)25.7518.118.6311.246.93
Net Profit Margin (%)19.2513.726.718.602.12
NP After MI And SOA Margin (%)19.2513.726.718.602.12
Return on Networth / Equity (%)23.3916.467.6010.262.28
Return on Capital Employeed (%)29.5720.059.3712.888.52
Return On Assets (%)16.3710.354.616.081.31
Long Term Debt / Equity (X)0.030.070.120.110.10
Total Debt / Equity (X)0.060.120.270.180.34
Asset Turnover Ratio (%)0.910.800.700.730.64
Current Ratio (X)2.151.731.601.491.44
Quick Ratio (X)1.331.100.870.810.82
Inventory Turnover Ratio (X)2.011.791.711.881.90
Dividend Payout Ratio (NP) (%)0.003.926.033.1830.53
Dividend Payout Ratio (CP) (%)0.002.963.412.1310.42
Earning Retention Ratio (%)0.0096.0893.9796.8269.47
Cash Earning Retention Ratio (%)0.0097.0496.5997.8789.58
Interest Coverage Ratio (X)33.9421.5510.729.104.90
Interest Coverage Ratio (Post Tax) (X)22.4413.515.735.501.75
Enterprise Value (Cr.)8068.902383.791534.952819.28564.23
EV / Net Operating Revenue (X)5.182.001.613.010.73
EV / EBITDA (X)16.988.4710.6117.315.33
MarketCap / Net Operating Revenue (X)5.201.951.392.870.47
Retention Ratios (%)0.0096.0793.9696.8169.46
Price / BV (X)6.322.341.583.430.51
Price / Net Operating Revenue (X)5.201.951.392.870.47
EarningsYield0.030.070.040.020.04

Neuland Laboratories Ltd Profitability Ratios (%)

Neuland Laboratories Ltd Liquidity Ratios

Neuland Laboratories Ltd Liquidity Ratios (%)

Neuland Laboratories Ltd Interest Coverage Ratios (%)

Neuland Laboratories Ltd Valuation Ratios

Fair Value

Fair Value: 9,176.37

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Undervalued: 12.87% compared to the current price 8130

Intrinsic Value: 16,633.05

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 104.59% compared to the current price 8130

Last 5 Year EPS CAGR: 81.26%

*Investments are subject to market risks

Strength and Weakness of Neuland Laboratories Ltd Stock

StrengthWeakness
  1. The company has higher reserves (571.67 cr) compared to borrowings (201.92 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (521.54 cr) and profit (84.23 cr) over the years.
  1. The stock has a low average ROCE of 11.83%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 115.58, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 161.67, which may not be favorable.

FAQ

What is the latest fair value of Neuland Laboratories Ltd?

The latest fair value of Neuland Laboratories Ltd is ₹9176.37.

What is the Market Cap of Neuland Laboratories Ltd?

The Market Cap of Neuland Laboratories Ltd is 10,431 Cr..

What is the current Stock Price of Neuland Laboratories Ltd as on 21 July 2024?

The current stock price of Neuland Laboratories Ltd as on 21 July 2024 is 8,130.

What is the High / Low of Neuland Laboratories Ltd stocks in FY 2024?

In FY 2024, the High / Low of Neuland Laboratories Ltd stocks is 8,650/3,100.

What is the Stock P/E of Neuland Laboratories Ltd?

The Stock P/E of Neuland Laboratories Ltd is 34.7.

What is the Book Value of Neuland Laboratories Ltd?

The Book Value of Neuland Laboratories Ltd is 1,000.

What is the Dividend Yield of Neuland Laboratories Ltd?

The Dividend Yield of Neuland Laboratories Ltd is 0.17 %.

What is the ROCE of Neuland Laboratories Ltd?

The ROCE of Neuland Laboratories Ltd is 33.3 %.

What is the ROE of Neuland Laboratories Ltd?

The ROE of Neuland Laboratories Ltd is 26.4 %.

What is the Face Value of Neuland Laboratories Ltd?

The Face Value of Neuland Laboratories Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Neuland Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE